A Phase 3 Study to Evaluate the Contraceptive Efficacy, Safety, and Tolerability of LPRI-CF113
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose (Part A) of this study is to evaluate the contraceptive efficacy, safety,
and tolerability of LPRI-CF113 for 12 months (13 medication cycles). In a subgroup of
subjects (Part B) 18 to 45 years of age (inclusive), bone mineral density (BMD) of the lumbar
spine, femoral neck, total hip, and total body will be assessed by dual-energy X-ray
absorptiometry (DXA) scan after 12 months (13 medication cycles).